ARTICLE | Top Story
ZymoGenetics, Bristol-Myers in HCV deal
January 13, 2009 2:22 AM UTC
ZymoGenetics (NASDAQ:ZGEN) and Bristol-Myers (NYSE:BMY) partnered to develop and commercialize PEG-Interferon lambda, an IL-29 in Phase Ib testing to treat HCV infection. The companies will co-develop...